Akebia Therapeutics (AKBA) Set to Announce Earnings on Thursday

by · The Cerbat Gem

Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.04) per share for the quarter.

Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02. The company had revenue of $43.65 million for the quarter, compared to analysts’ expectations of $45.61 million. During the same period in the previous year, the business earned ($0.06) EPS. On average, analysts expect Akebia Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Akebia Therapeutics Trading Up 1.8 %

Shares of AKBA stock opened at $1.69 on Friday. Akebia Therapeutics has a 12-month low of $0.80 and a 12-month high of $2.48. The stock has a market capitalization of $355.39 million, a P/E ratio of -8.05 and a beta of 0.77. The firm’s 50 day moving average is $1.43 and its 200 day moving average is $1.29.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $7.50 price objective on shares of Akebia Therapeutics in a research note on Wednesday, October 23rd.

Check Out Our Latest Stock Report on Akebia Therapeutics

About Akebia Therapeutics

(Get Free Report)

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.

Featured Articles